Relapsed or Refractory Acute Myeloid Leukemia (AML) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Relapsed or Refractory Acute Myeloid Leukemia Emerging Therapy and TPP Insights

Thelansis’s “Relapsed or Refractory Acute Myeloid Leukemia (AML) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Relapsed or Refractory Acute Myeloid Leukemia Overview

Relapsed or refractory acute myeloid leukemia (R/R AML) persists after initial treatment or returns after remission. Malignant myeloid cells crowd the bone marrow, reducing normal blood-cell production and causing anemia, infections, bleeding, and fatigue. Treatment depends on prior therapy, fitness, transplant eligibility, and molecular findings. Options include salvage chemotherapy and allogeneic stem-cell transplantation for suitable patients, alongside targeted agents for selected mutations. Gilteritinib is used for FLT3-mutated AML; ivosidenib or enasidenib may suit susceptible IDH1 or IDH2 mutations. Menin inhibitors offer options for defined subgroups: revumenib is approved for KMT2A-translocated acute leukemia and susceptible NPM1-mutated R/R AML; ziftomenib is approved for adults with susceptible NPM1-mutated disease who lack satisfactory alternatives. Relapse remains difficult to treat, making molecular testing and clinical trials important.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)